EUCTR2017-003511-20-NL进行中（未招募）1 期
Molecular imaging of zirconium-89-labeled atezolizumab in high-risk diffuse large B-cell lymphoma prior to atezolizumab treatment - PDL1 imaging in DLBC
HOVON Foundation0 个研究点目标入组 20 人开始时间: 2018年9月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •In order to receive information on the dynamics induced by R-CHOP, patients should preferably be included before standard R-CHOP therapy (at Part A). Alternatively, patients who are eligible can also be included after having achieved complete remission with standard R-CHOP therapy (i.e. at Part B).
- •Inclusion criteria
- •Age 18-75 (inclusive) years
- •Patients with a confirmed histologic diagnosis of diffuse large B-cell lymphoma (DLBCL-NOS) based upon a representative histology specimen according to the WHO classification, revision 2016 (see appendix A)
- •Ann Arbor stages II-IV (see appendix B)
- •WHO performance status 0 – 1 (see appendix E)
- •IPI = 3 at diagnosis (see appendix C)
- •Negative pregnancy test at study entry
- •Patient is willing and able use adequate contraception during and until 5 months after the last protocol treatment.
- •Written informed consent
- •Patient is capable of giving a written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •All histopathological diagnoses other than DLBCL-NOS according to the WHO classification, revision 2016 (see appendix A), including:
- •- High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 translocations
- •- Testicular large B-cell lymphoma
- •- Primary mediastinal B cell lymphoma
- •- Transformed indolent lymphoma
- •- Post-transplant lymphoproliferative disorder
- •Organ dysfunction
- •Clinical signs of severe pulmonary dysfunction
- •Clinical signs of heart failure (NYHA classification II-IV)
- •Symptomatic coronary artery disease or cardiac arrhythmias not well controlled with medication.
- •Myocardial infarction during the last 6 months
- •Significant renal dysfunction (serum creatinine = 150 umol/l or clearance = 30ml/min
- •Creatinine clearance may be calculated by Cockcroft –Gault formula:
- •CrCl = (140 - age [in years]) x weight [kg] (x 0.85 for females) /
- •(0.815 x serum creatinine [µmol/L])
- •Inadequate hematological function: hemoglobin < 5.5 mmol/L ANC < 1.0x10^9/L or platelets < 75x10^9 /L
- •Spontaneous INR > 1.5, aPTT >33
- •Significant hepatic dysfunction (total bilirubin = 1.5x upper limit of normal (ULN) or transaminases = 2.5 x ULN), unless related to Gilberts syndrome.
- •Clinical signs of severe cerebral dysfunction
- •Patients with a history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs
- •Major surgery within the last 4 weeks
- •Known or suspected infection
- •Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks before date of registration. Suspected active or latent tuberculosis needs to be confirmed by positive interferon gamma (IFN-?) release assay
- •Patients known to be HIV-positive
- •Active chronic hepatitis B or C infection
- •Administration of a live, attenuated vaccine within 4 weeks before date of registration or anticipation that such a live attenuated vaccine will be required during the study and for a period of 5 months after discontinuation of atezolizumab.
- •Auto-immune
- •Any active or history of documented autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener’s granulomatosis, Sjögren’s syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
- •The following exceptions are allowed: Patients with autoimmune-related hypothyroidism or type 1 diabetes mellitus who are on stable treatment.
- •History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidenc
研究者
相似试验
尚未招募
2 期
Molecular imaging of zirconium-89-labeled atezolizumab as a tool to investigate atezolizumab biodistribution in diffuse large B-cell lymphomadiffuse large B-cell lymphomalymphomaNL-OMON48775HOVO20
尚未招募
不适用
Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive LymphomaHodgkin lymphomaNL-OMON51758niversitair Medisch Centrum Groningen20
撤回
不适用
Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma PatientsDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedNCT03850028University Medical Center Groningen
进行中（未招募）
1 期
Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast CancerCTIS2022-500808-21-00Karolinska University Hospital64
尚未招募
2 期
A Phase IIB, Open Label, Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET-CT in Subjects with Selected Advanced or Metastatic Malignancies including Melanoma, Merkel Cell, Renal Cell and Non-Small Cell Lung Cancers, Scheduled to Receive Standard-of-Care Immunotherapy (IOT) as a Single Agent or Combination, to Predict Response to TherapyNL-OMON54060ImaginAb, Inc.30